GOSR1 Knockout HeLa Polyclonal Cells are a polyclonal knockout cell population generated by CRISPR/Cas9-mediated disruption of the GOSR1 gene in the HeLa cell line. This loss-of-function model enables detailed investigation of ER-to-Golgi trafficking, Golgi organization, and secretory pathway dynamics. The polyclonal design is well-suited for functional studies without clonal selection biases.
HeLa cells are an immortalized human cervical adenocarcinoma cell line extensively used in cancer and cell biology research. Their transformed nature and rapid division make them a robust platform for examining secretory pathway alterations, as defects in protein trafficking and glycosylation are hallmarks of malignancy. This host background provides a physiologically relevant system to study GOSR1 function in both normal and disease states.
GOSR1 encodes a SNARE protein essential for vesicle fusion at the ER?CGolgi interface. It forms a quaternary complex with BET1, SEC22B, and STX5 to mediate docking and fusion of COPII vesicles with the cis-Golgi. Upstream, the SAR1 GTPase initiates COPII coat assembly via SEC23/SEC24 and SEC13/SEC31 complexes, generating transport carriers. After fusion, the SNARE complex is disassembled with the aid of NSFL1C. Thus, GOSR1 knockout disrupts cargo delivery to the Golgi, leading to ER accumulation of secretory proteins and impaired downstream processing.
In HeLa cells, GOSR1 knockout produces a characteristic phenotype of Golgi fragmentation, ER retention of cargo, and defective protein secretion. These defects are relevant to congenital disorders of glycosylation and highlight the role of GOSR1 in maintaining Golgi structure and function. The cancerous origin of HeLa cells makes this model particularly useful for studying how trafficking perturbations contribute to oncogenic processes, including altered receptor presentation and aberrant secretion.
Key applications include monitoring Golgi morphology via GM130 immunofluorescence, assessing secretory kinetics with VSVG-EGFP reporters, and confirming knockout efficiency by Western blot. Co-immunoprecipitation of SNARE partners (e.g., BET1, STX5) and secretion assays further enable functional dissection. The model is applicable to cancer, glycosylation, and neurodegeneration research. For further information, contact Ascent Research.
